Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136425 | 1.00 | BTK (0.52) | BTKMMP2MMP13EGFRMAOB | |
| SCHEMBL1136433 | 0.95 | BTK (0.57) | BTKMMP2MMP13EGFRMAOB | |
| SCHEMBL1136434 | 0.95 | BTK (0.57) | BTKMMP2MMP13EGFRMAOB | |
| SCHEMBL1136399 | 0.92 | BTK (0.53) | BTKEGFRNPC1RAB9A | |
| SCHEMBL1136400 | 0.92 | BTK (0.53) | BTKEGFRNPC1RAB9A | |
| SCHEMBL4599400 | 0.89 | MMP2 (0.51) | BTKMMP2MMP13MAOBNR2E3 | |
| SCHEMBL1136372 | 0.88 | BTK (0.49) | BTKMMP2MMP13EGFRALDH1A1 | |
| SCHEMBL1136373 | 0.88 | BTK (0.49) | BTKMMP2MMP13EGFRALDH1A1 | |
| SCHEMBL1136387 | 0.85 | BTK (0.49) | BTKALDH1A1LMNAMAPTHTT | |
| SCHEMBL1136385 | 0.85 | BTK (0.49) | BTKALDH1A1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919910-B1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | claimed |
| EP-1919910-B1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | disclosed |
| EP-1919910-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. Hoffmann-la Roche AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007017143-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | AZI2, CDKN1A, CCNI | BTK 1849/4885MMP2 1903/4885MMP13 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.